• 1. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198
• 2. Emerging investigators
  Polym. Chem., 2015,6, 5501-5502
• 3. Ester-mediated peptide formation promoted by deep eutectic solvents: a facile pathway to proto-peptides?
  Chen-Yu Chien,Sheng-Sheng Yu Chem. Commun., 2020,56, 11949-11952
• 4. Excitation dependent bidirectional electron transfer in phthalocyanine-functionalised MoS2 nanosheets?
  Christopher J. Harrison,Kyle J. Berean,Enrico Della Gaspera,Jian Zhen Ou,Richard B. Kaner,Kourosh Kalantar-zadeh,Torben Daeneke Nanoscale, 2016,8, 16276-16283
• 5. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives

Introduction to (S)-2-Amino-4-((tert-butoxycarbonyl)amino)butanoic Acid (CAS No. 10270-94-7)

(S)-2-Amino-4-((tert-butoxycarbonyl)amino)butanoic Acid, identified by its CAS number 10270-94-7, is a significant compound in the field of pharmaceutical chemistry and biochemistry. This compound, featuring a chiral center, has garnered considerable attention due to its utility as an intermediate in the synthesis of various pharmacologically active molecules. The presence of both amino and carbamate functional groups makes it a versatile building block for the development of novel therapeutic agents.

The (S)-configuration of this compound is particularly noteworthy, as enantiomeric purity is often crucial in drug development to ensure optimal biological activity and minimize adverse effects. The tert-butoxycarbonyl (Boc) group, a protecting group for amines, further enhances the compound's utility in multi-step synthetic routes. This protection allows for selective manipulation of other functional groups while maintaining the integrity of the amine moiety, which is essential in complex molecular constructions.

In recent years, there has been a growing interest in the development of peptidomimetics, which are synthetic analogs of natural peptides designed to mimic their biological functions but with improved pharmacokinetic properties. (S)-2-Amino-4-((tert-butoxycarbonyl)amino)butanoic Acid has been employed in the synthesis of such peptidomimetics due to its ability to incorporate into peptide chains with high fidelity. The rigid structure provided by the Boc group also aids in stabilizing the conformation of these mimetics, enhancing their binding affinity and selectivity.

Furthermore, this compound has found applications in the field of enzyme inhibition studies. Its structural motif closely resembles that of certain natural amino acids, making it an effective substrate or inhibitor for enzymes involved in metabolic pathways. For instance, researchers have utilized derivatives of (S)-2-Amino-4-((tert-butoxycarbonyl)amino)butanoic Acid to study the kinetics and mechanisms of amino acid transporters and metabolic enzymes. Such studies are pivotal in understanding disease pathologies and developing targeted therapies.

The synthesis of (S)-2-Amino-4-((tert-butoxycarbonyl)amino)butanoic Acid typically involves chiral resolution or asymmetric synthesis methods to ensure high enantiomeric purity. Advances in catalytic asymmetric transformations have enabled more efficient and scalable production processes for this compound. These methods often employ transition metal catalysts or biocatalysts, which offer superior selectivity and reduced environmental impact compared to traditional chemical synthesis routes.

In the context of drug discovery, (S)-2-Amino-4-((tert-butoxycarbonyl)amino)butanoic Acid has been incorporated into various lead compounds targeting different therapeutic areas. For example, its structural framework has been utilized in the design of protease inhibitors for antiviral and anticancer applications. The Boc group can be removed under specific conditions to introduce reactive amine functionalities, allowing further derivatization into more complex drug molecules.

Recent studies have also explored the use of (S)-2-Amino-4-((tert-butoxycarbonyl)amino)butanoic Acid in peptide-based therapeutics. Its ability to form stable peptide bonds and its compatibility with solid-phase peptide synthesis make it an attractive choice for constructing novel biologics. These therapeutics have shown promise in treating a range of diseases, including inflammatory disorders and neurodegenerative conditions.

The compound's role in medicinal chemistry extends beyond its use as a building block. It serves as a valuable tool for investigating protein-protein interactions and enzyme-substrate recognition. By modifying its structure or substituting functional groups, researchers can generate libraries of compounds with tailored properties for high-throughput screening assays. This approach has accelerated the discovery of new drug candidates by enabling rapid evaluation of large chemical spaces.

Additionally, (S)-2-Amino-4-((tert-butoxycarbonyl)amino)butanoic Acid has been employed in the development of new analytical methods for chiral separations. Techniques such as chromatography and spectroscopy benefit from its use as a reference standard or derivatization agent, improving the accuracy and reliability of enantiomeric purity assessments in pharmaceutical formulations.

As research continues to evolve, the applications of (S)-2-Amino-4-((tert-butoxycarbonyl)amino)butanoic Acid are expected to expand further. Emerging fields such as precision medicine and personalized therapeutics will likely leverage its unique structural features for designing bespoke treatments tailored to individual patient needs. The compound's versatility and well-documented synthetic protocols make it an indispensable asset in modern drug discovery pipelines.

• 25691-37-6(Boc-L-2,4-diaminobutyric acid)
• 31202-69-4(Nε-Boc-D-lysine)
• 3350-15-0((2S)-2-Amino-4-(1,1-dimethylethoxy)carbonylaminobutanoic Acid Methyl Ester Hydrochloride)
• 114360-55-3(H-D-Dab(boc)-OH)
• 80449-06-5(Restriction Endonuclease Rsa I (high conc.))
• 80445-78-9(Boc-d-dab-oh)
• 2418-95-3((S)-2-Amino-6-((tert-butoxycarbonyl)amino)hexanoic acid)
• 13650-49-2(N-δ-Boc-L-Ornithine)
• 2899-79-8(4-Amino-2-((tert-butoxycarbonyl)amino)butanoic acid)
• 184576-63-4(N-δ-BOC-D-Ornithine)